Researchers Call for Expansion of Mint Tobacco Ban

Dec.08.2022
Researchers Call for Expansion of Mint Tobacco Ban
Researchers urge FDA to expand ban on mint-flavored tobacco products to include potential substitutes like mint pipes and cigarillos.

Researchers from the Rutgers Tobacco Research Center and Ohio State University are calling for the US Food and Drug Administration (FDA) to expand the ban on mint-flavored cigarettes and cigars to include potential alternatives like mint-flavored pipes and rolling papers.


According to a study published in the journal Tobacco Control, researchers are urging the FDA to maximize the benefits of the ban on menthol-flavored cigarettes based on new evidence showing that these alternatives are attractive and have the potential to be addictive for adults who smoke menthol cigarettes.


Andrea Villanti, Associate Director of the Rutgers University Tobacco Research Center, stated that tobacco companies have renamed their roll-your-own tobacco as pipe tobacco to avoid taxes, and have branded flavored cigarettes as flavored cigars to evade federal bans. Villanti, the lead researcher of the study, said, "We have seen companies promoting pipe tobacco and cigarillos alongside cigarettes and filtered cigars. The products we tested in our research are likely the ones tobacco companies will promote after mint-flavored cigarettes are banned.


Researchers examined 98 adults who smoked menthol cigarettes to compare the addictive potential of combustible menthol with its substitutes. The study was conducted in four parts over a three-week period, during which participants first smoked their usual brand of menthol cigarettes. In the next three sessions, participants were randomly assigned three different menthol cigarette substitutes:


One cigarette that does not contain menthol alcohol is a pre-assembled menthol cigarette made with mint tobacco and a menthol pipe for filtering. It also includes a small menthol cigar.


During each meeting, researchers measured the smoking habits of participants, including the amount of carbon monoxide emitted, cravings, and withdrawal symptoms. Participants also self-reported their perceived effects of the drug and evaluated other measures of addiction potential for each product.


The team discovered that while menthol-filtered small cigars and non-mentholated cigarettes are attractive alternatives to menthol cigarettes, menthol pipe tobacco and rolling papers are the most alluring and lead to the highest number of indicators for future nicotine addiction. However, these products have not been considered for inclusion in the proposed ban.


According to the investigation results, the components of menthol cigarette products, including menthol paper, cigarette tube, and tobacco for pipe, should be included in the standards for menthol cigarettes and flavored cigars, as stated by Villanti.


Previous research has established a correlation between the use of menthol-flavored cigarettes and an increase in smoking initiation, nicotine dependence, and reduced adult smoking cessation, particularly among vulnerable populations. The FDA has proposed a regulation prohibiting the use of menthol as a flavoring agent in cigarettes and cigars to address this public health concern. Following a review of public feedback, a final decision is expected to be made in the coming months.


Currently, research results indicate that the components of menthol cigarette products, including menthol cigarette paper, filters, and tobacco, should be included in the standards for menthol cigarettes and flavored cigars," said Theodore Wagener, director of the center. The research was conducted by the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, and the lead author of the study. "Failing to comply with this restriction would result in a serious loophole that the tobacco industry has already exploited and could potentially weaken the potential public health benefits of the proposed menthol ban.


2FIRSTS will continue to provide ongoing coverage of this topic, with further updates available on the "2FIRSTSAPP" platform. Scan the QR code below to download the app.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Imperial Brands' acquisition of Swedish Helwit owner Yoik Group AB has highlighted the professional-services firms supporting cross-border oral nicotine M&A. Latham & Watkins and KPMG advised Imperial, while PwC and TM & Partners advised Yoik. KPMG also appeared on Imperial's acquisition of Black Buffalo earlier in 2026, while PwC played an extensive role in KT&G's acquisition of Swedish nicotine-pouch company Another Snus Factory. Imperial's public disclosures put the global modern oral nicotine delivery market at approximately £8.8 billion in retail sales and 23.5 billion pouches in 2024
Sep.20
FDA Authorizes JUUL2, Cites Adult Switching Amid Efforts to Speed PMTA Reviews
FDA Authorizes JUUL2, Cites Adult Switching Amid Efforts to Speed PMTA Reviews
The FDA authorized the JUUL2 device and tobacco- and menthol-flavored pods on Aug. 28, bringing the number of authorized e-cigarette products to 48. The agency highlighted complete switching among adult smokers, with six-week switching rates reaching 28.4%–49.3% for the menthol pod. The decision comes as FDA works to speed PMTA reviews, reduce application backlogs and expand authorized e-cigarette and nicotine-pouch products while maintaining enforcement priorities for unauthorized products.
Regulations
Aug.29
Product | PMI Japan Launches SENTIA Passion Fruit Capsule, Expanding the IQOS ILUMA Flavor Portfolio
Product | PMI Japan Launches SENTIA Passion Fruit Capsule, Expanding the IQOS ILUMA Flavor Portfolio
Philip Morris Japan (PM Japan) has introduced SENTIA Passion Fruit Capsule, a new tobacco stick designed for the IQOS ILUMA heated tobacco platform. Featuring a crush-activated capsule, the product combines menthol with passion fruit flavor to provide an additional flavor experience. The product launched in Japan from August 3, 2026, through IQOS official channels, convenience stores and tobacco retailers.
Aug.04
U.S. House Defense Bill Includes Pilot Review of Vapes, Nicotine Pouches and Heated Tobacco for Military Smokers
U.S. House Defense Bill Includes Pilot Review of Vapes, Nicotine Pouches and Heated Tobacco for Military Smokers
On July 23, 2026, the U.S. House of Representatives passed its version of the Fiscal Year 2027 National Defense Authorization Act (NDAA), which includes Section 707 provisions requiring the Department of Defense to evaluate tobacco use and nicotine alternatives among military personnel. The pilot program would examine products including vapes, nicotine pouches and heated tobacco products, primarily among active-duty service members who continue using combustible tobacco. The provision is a policy evaluation effort, not an authorization for military vaping promotion or a ban on vape products.
Jul.28
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
China’s Jiangsu Tobacco Monopoly Bureau and Drug Regulator Target Illegal Vape Sales Disguised as Medical Devices, Define Six Violations
China’s Jiangsu Tobacco Monopoly Bureau and Drug Regulator Target Illegal Vape Sales Disguised as Medical Devices, Define Six Violations
China’s Jiangsu Tobacco Monopoly Bureau and Jiangsu Provincial Medical Products Administration have issued a joint notice targeting illegal production and sales of vape products disguised as medical devices. The notice identifies six categories of violations, including obtaining medical licenses through false materials, misusing medical device credentials, expanding production beyond approved scopes, and using medical device-related online platforms to promote or sell vape products. The action is based on China’s tobacco and medical device regulations and aims to strengthen vape oversight and consumer protection.
Aug.04